Skip to main content
SpringerLink
Log in

Pharmacotherapy of First Episode Psychosis

  • Chapter
Early Intervention in Psychotic Disorders

Part of the book series: NATO Science Series ((ASID,volume 91))

Abstract

In recent years researchers have increased their focus on the initial stages of schizophrenia, with the hope that a better understanding at this point will maximize our potential to intervene effectively early and, in doing so, improve the often rapid and debilitating course of this illness.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rabiner, C.J., Wegner, J.T., and Kane, J.M. (1986) Outcome study of first-episode psychosis. I: Relapse rates after 1 year, Am. J Psychiatry 143, 1155-1158.

    PubMed  CAS  Google Scholar 

  2. Lieberman, J., Jody, D., Geisler, S., Vital-Herne, J., Alvir, J.M., Walsieben, J., and Woerner, M.G. (1989) Treatment outcome of first episode schizophrenia, Psychopharmacol. Bull. 25 92-96.,

    PubMed  CAS  Google Scholar 

  3. Lieberman, J., Jody, D., Geisler, S., Alvir, J., Loebel, A., Szymanski, S., Woemer, M., and Borenstein, M. (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia, Arch. Gen. Psychiatry 50 369-376.,

    Article  PubMed  CAS  Google Scholar 

  4. Gupta, S., Andreasen, N.C., Arndt, S., Flaum, M., Hubbard, W.C., and Ziebell, S. (1997) The Iowa Longitudinal Study of Recent Onset Psychosis: one-year follow-up of first episode patients, Schizophr. Res. 23 1-13.,

    Article  PubMed  CAS  Google Scholar 

  5. Robinson, D.G., Woerner, M.G., Alvir, J.M., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., and Lieberman, J.A. (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder, Am. J. Psychiatry 156 544-549.,

    PubMed  CAS  Google Scholar 

  6. Lieberman, J.A., Koreen, A.R., Chakos, M., Sheitman, B., Woemer, M., Alvir, J.M., and Bilder, R. (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia, J. Clin. Psychiatry 57 5-9.,

    PubMed  Google Scholar 

  7. Loebel, A.D., Lieberman, J.A., Alvir, J.M., Mayerhoff, D.I., Geisler, S.H., and Szymanski, S.R. (1992) Duration of psychosis and outcome in first-episode schizophrenia, Am. J Psychiatry 149 1183-1188.,

    PubMed  CAS  Google Scholar 

  8. . Scully, P.J., Coakley, G., Kinsella, A., and Waddington, J.L. (1997) Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia, Psychol. Med. 27, 1303-1310.

    Article  PubMed  CAS  Google Scholar 

  9. Wyatt, R.J., Green, M.F., and Tuma, A.H. (1997) Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data, Psychol. Med. 27 261-268.,

    Article  PubMed  CAS  Google Scholar 

  10. Saugstad, L.F. (1994) The maturational theory of brain development and cerebral excitability in the multifactorially inherited manic-depressive psychosis and schizophrenia, Int. J Psychophysiol., 18 189203.

    Google Scholar 

  11. Weinberger, D.R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia, Arch. Gen. Psychiatry 44 660-669.,

    Article  PubMed  CAS  Google Scholar 

  12. Shapiro, R.M. (1993) Regional neuropathology in schizophrenia: where are we? Where are we going?, Schizophr. Res. 10 187-239.,

    Article  PubMed  CAS  Google Scholar 

  13. Murray, R.M. (1994) Neurodevelopmental schizophrenia: the rediscovery of dementia praecox, Br. J. Psychiatry 165 6-12.,

    Google Scholar 

  14. Weinberger, D.R., and Lipska, B.K. (1995) Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground, Schizophr. Res. 16, 87-110.

    Article  PubMed  CAS  Google Scholar 

  15. Weinberger, D.R. (1997) The biological basis of schizophrenia: new directions, J Clin. Psychiatry 58 22-27.,

    Article  PubMed  Google Scholar 

  16. Bullmore, E.T., Frangou, S., and Murray, R.M. (1997) The dysplastic net hypothesis: an integration of developmental and dysconnectivity theories of schizophrenia, Schizophr. Res.28, 143-156.

    Google Scholar 

  17. Woods, B.T. (1998) Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism, Am. J Psychiatry 155, 1661-1670.

    PubMed  CAS  Google Scholar 

  18. Hyde, T.M., Nawroz, S., Goldberg, T.E., Bigelow, L.B., Strong, D., Ostrem, J.L., Weinberger, D.R., and Kleinman, J.E. (1994) Is there cognitive decline in schizophrenia? A cross-sectional study, Br. J Psychiatry 164, 494-500.

    Article  PubMed  CAS  Google Scholar 

  19. Russell, A.J., Munro, J.C., Jones, P.B., Hemsley, D.R., and Murray, R.M. (1997) Schizophrenia and the myth of intellectual decline, Am. J Psychiatry 154, 635-639.

    PubMed  CAS  Google Scholar 

  20. Hafner, H., and ander Heiden, W. (1997) Epidemiology of schizophrenia, Can. J Psychiatry 42 139151.,

    Google Scholar 

  21. Haas, G.L., and Sweeney, J.A. (1992) Premorbid and onset features of first-episode schizophrenia, Schizophr. Bull. 18 373-386.,

    Article  PubMed  CAS  Google Scholar 

  22. McGorry, P.D. (1994) The influence of illness duration on syndrome clarity and stability in functional psychosis: does the diagnosis emerge and stabilise with time?, Aust. N. Z. J Psychiatry 28 607-619.,

    Article  PubMed  CAS  Google Scholar 

  23. Wyatt, R.J. (1995) Risks of withdrawing antipsychotic medications, Arch. Gen. Psychiatry 52, 205-208.

    Article  PubMed  CAS  Google Scholar 

  24. Jackson, H.J., McGorry, P.D., and Dudgeon, P. (1995) Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity Compr. Psychiatry 36 241-250.,

    Article  PubMed  CAS  Google Scholar 

  25. Yung, A.R., and McGorry, P.D. (1996) The prodromal phase of first-episode psychosis: past and current conceptualizations, Schizophr. Bull. 22 353-370.,

    Article  PubMed  CAS  Google Scholar 

  26. Gross, G. (1997) The onset of schizophrenia, Schizophr. Res. 28 187-198.,

    Article  PubMed  CAS  Google Scholar 

  27. Fennig, S., Kovasznay, B., Rich, C., Ram, R., Pato, C., Miller, A., Rubinstein, J., Carlson, G., Schwartz, J.E., Phelan, J., Lavelle, J., Craig, T., and Bromet, E. (1994) Six-month stability of psychiatric diagnoses in first-admission patients with psychosis, Am. J. Psychiatry 151 1200-1208.,

    PubMed  CAS  Google Scholar 

  28. Munk-Jorgensen, P. (1985) The schizophrenia diagnosis in Denmark. A register-based investigation, Acta Psychiatr. Scand. 72 266-273.,

    Article  PubMed  CAS  Google Scholar 

  29. Lenz, G., Simhandl, C., and Thau, K. (1992) Temporal stability and predictive validity of diagnostic criteria for schizophrenia, Schizophr. Res. 6 170.,

    Article  Google Scholar 

  30. Phillips L.J., McGorry, P.D., Yung A.R., Francey, S., Cosgrave, L., Germano, D., Bravin, J., MacDonald, A., Hallgren, M., Hearn, N., Adlard, S., and Patton, G. (1999) The development of preventive interventions for early psychosis: early findings and directions for the future, Schizophr. Res. 36 331-332.,

    Google Scholar 

  31. Kane, J.M. (1996) Schizophrenia, N. Engl. J. Med. 334 34-41.,

    Article  PubMed  CAS  Google Scholar 

  32. Remington, G., Kapur, S., and Zipursky, R.B. (1998) Pharmacotherapy of first-episode schizophrenia, Br. J Psychiatry 1721Supp1.1 66-70.,

    Google Scholar 

  33. Emsley, R., McCreadie, R., Livingston, M., De Smedt, G., and Lemmens, P. (1995) Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study, 8th European Conference of Neuropsychopharmacology, Venice, Italy.

    Google Scholar 

  34. Sanger, T.M., Lieberman, J.A., Tohen, M., Grundy, S., Beasley, C., Jr., and Tollefson, G.D. (1999) Olanzapine versus haloperidol treatment in first-episode psychosis, Am. J Psychiatry 156 79-87.,

    PubMed  CAS  Google Scholar 

  35. Purdon, S.E. (1999) Cognitive improvement in schizophrenia with novel antipsychotic medications, Schizophr Res 35 1Suppl .1 S51-60.,

    Article  Google Scholar 

  36. Canadian Cognition and Outcome Study Group. (1998) Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol, Schizophr. Res. 29 152-153.,

    Google Scholar 

  37. Kane, J. (1997) Outcomes: relapse and tardive dyskinesia, 150th Annual Meeting of the American Psychiatric Association, San Diego, California.

    Google Scholar 

  38. Juul Povlsen, U., Noring, U., Fog, R., and Gerlach, J. (1985) Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years, Acta. Psychiatr. Scand 71 176-185.,

    Article  PubMed  CAS  Google Scholar 

  39. Peacock, L., Solgaard, T., Lublin, H., and Gerlach, J. (1996) Clozapine versus typical antipsychotics. A retro-and prospective study of extrapyramidal side effects, Psychopharmacology (Berl) 124 188-196.,

    Article  CAS  Google Scholar 

  40. Brecher, M., and Burks, E. (1996) Long-term safety of risperidone: results of seven 1-year trials, American College of Clinical Pharmacy, Nashville, TN.

    Google Scholar 

  41. Tollefson, G.D., Beasley, C.M., Jr., Tamura, R.N., Tran, P.V., and Potvin, J.H. (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol, Am. J Psychiatry 154 1248-1254.,

    PubMed  CAS  Google Scholar 

  42. Mukherjee, S., Rosen, A.M., Cardenas, C., Varia, V., and Olarte, S. (1982) Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables, Arch. Gen. Psychiatry 39 466-469.,

    Article  PubMed  CAS  Google Scholar 

  43. Chouinard, G., Annable, L., Ross-Chouinard, A., and Mercier, P. (1988) A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases, J Clin. Psychopharmacol. 8 21S-26S.,

    Article  PubMed  CAS  Google Scholar 

  44. O'Hara, P., Brugha, T.S., Lesage, A., and Wing, J. (1993) New findings on tardive dyskinesia in a community sample, Psycho!. Med. 23 453-465.,

    Article  Google Scholar 

  45. Jeste, D.V., Lacro, J.P., Palmer, B., Rockwell, E., Harris, M.J., and Caligiuri, M.P. (1999) Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients, Am. J. Psychiatry 156 309-311.,

    PubMed  CAS  Google Scholar 

  46. Umbricht, D., and Kane, J.M. (1996) Medical complications of new antipsychotic drugs, Schizophr. Bull. 22475-483.,

    Article  PubMed  CAS  Google Scholar 

  47. Casey, D.E. (1997) The relationship of pharmacology to side effects, J Clin. Psychiatry 58 55-62.,

    PubMed  CAS  Google Scholar 

  48. Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J., Mintz, J., and Marder, S.R. (1999) Novel antipsychotics: comparison of weight gain liabilities, J Clin. Psychiatry 60 358-363.,

    Article  PubMed  CAS  Google Scholar 

  49. Pi-Sunyer, F.X. (1993) Medical hazards of obesity, Ann. Int. Med. 119 655-660.,

    Article  PubMed  CAS  Google Scholar 

  50. Chengappa, K.N.R., Pelucio, M., Baker, R.W., and Cole, D. (1995) Recurrent pancreatitis on clozapine re-challenge, J Psychopharmacol. 9 381-382.,

    Article  PubMed  CAS  Google Scholar 

  51. Fertig, M.K., Brooks, V.G., Shelton, P.S., and English, C.W. (1998) Hyperglycemia associated with olanzapine, J Clin. Psychiatry 59 687-689.,

    Article  PubMed  CAS  Google Scholar 

  52. Hagg, S., Joelsson, L., Mjorndal, T., Spigset, O., Oja, G., and Dahlqvist, R. (1998) Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications, J. Clin. Psychiatry 59 294-299.,

    Article  PubMed  CAS  Google Scholar 

  53. Kamran, A., Doraiswamy, P.M., Jane, J.L., Hammett, E.B., and Dunn, L. (1994) Severe hyperglycemia associated with high doses of clozapine, Am. J Psychiatry 151 1395.,

    PubMed  CAS  Google Scholar 

  54. Kostakoglu, A.E., Yazici, K.M., Erbas, T., and Guvener, N. (1996) Ketoacidosis as a side-effect of clozapine: a case report, Acta. Psychiatr. Scand. 93 217-218.,

    Article  PubMed  CAS  Google Scholar 

  55. Koval, M.S., Rames, L.J., and Christie, S. (1994) Diabetic ketoacidosis associated with clozapine treatment, Am. J. Psychiatry 151 1520-1521.,

    PubMed  CAS  Google Scholar 

  56. Peterson, G.A., and Byrd, S.L. (1996) Diabetic ketoacidosis from clozapine and lithium cotreatment, Am. J. Psychiatry 153 737-738.,

    Google Scholar 

  57. Popli, A.P., Konicki, P.E., Jurjus, G.J., Fuller, M.A., and Jaskiw, G.E. (1997) Clozapine and associated diabetes mellitus, J Clin. Psychiatry 58 108-111.,

    Article  PubMed  CAS  Google Scholar 

  58. Wirshing, D.A., Spellberg, B.J., Erhart, S.M., Marder, S.R., and Wirshing, W.C. (1998) Novel antipsychotics and new onset diabetes, Biol. Psychiatry 44 778-783.,

    Article  PubMed  CAS  Google Scholar 

  59. Baldessarini, R.J., Katz, B., and Cotton, P. (1984) Dissimilar dosing with high-potency and low-potency neuroleptics, Am. J. Psychiatry 141 748-752.,

    PubMed  CAS  Google Scholar 

  60. Baldessarini, R.J., Cohen, B.M., and Teicher, M.H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses, Arch. Gen. Psychiatry 45 79-91.,

    Article  PubMed  CAS  Google Scholar 

  61. Farde, L., Nordstrom, A.L., Wiesel, F.A., Pauli, S., Halldin, C., and Sedvall, G. (1992) Positron emission tomographic analysis of central DI and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects, Arch. Gen. Psychiatry 49 538-544.,

    Article  PubMed  CAS  Google Scholar 

  62. Nordstrom, A.L., Farde, L., Wiesel, F.A., Forslund, K., Pauli, S., Halldin, C., and Uppfeldt, G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients, Biol. Psychiatry 33, 227-235.

    Article  PubMed  CAS  Google Scholar 

  63. Kapur, S., Zipursky, R.B., and Remington, G. (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia, Am. J Psychiatry 156, 286-293.

    PubMed  CAS  Google Scholar 

  64. Kapur, S., Remington, G.J., Jones, C., Zipursky, R.B. (1999) Does dopamine D2 occupancy predict antipsychotic response and side effects? A randomised double-blind test of the hypothesis, Schizophr. Res . 36, 242.

    Google Scholar 

  65. Wolkin, A., Barouche, F., Wolf, A.P., Rotrosen, J., Fowler, J.S., Shiue, C.Y., Cooper, T.B., and Brodie, J.D. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia, Am. J. Psychiatry 146, 905-908.

    PubMed  CAS  Google Scholar 

  66. Coppens, H.J., Slooff, C.J., Paans, A.M., Wiegman, T., Vaalburg, W., and Korf, J. (1991) High central Ds-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients, Biol. Psychiatry 29, 629-634.

    Article  PubMed  CAS  Google Scholar 

  67. Daskalakis, Z.J., Kapur, S., Jones, C., Zipursky, R.B. (1999) Dopamine D2 occupancy predicts prolactin elevation: a prospective clinical-PET investigation, International Congress on Schizophrenia Research, Santa Fe, New Mexico.

    Google Scholar 

  68. Kapur, S., Remington, G., Jones, C., Wilson, A., DaSilva, J., Iloule, S., and Zipursky, R. (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study, Am. J Psychiatry 153, 948-950.

    PubMed  CAS  Google Scholar 

  69. Nyberg, S., Nakashima, Y., Nordstrom, A.-L., Halldin, C., and Farde, L. (1996) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs: review of D2 and 5-HT2 receptor occupancy studies and clinical response, Br. J. Psychiatry 168]Suppl. 29], 40-44.

    Google Scholar 

  70. Farde, L., Hall, H., Ehrin, E., and Sedvall, G. (1986) Quantitative analysis of D, dopamine receptor binding in the living human brain by PET, Science 231, 258-261.

    Article  PubMed  CAS  Google Scholar 

  71. Koreen, A.R., Lieberman, J., Alvir, J., Chakos, M., Loebel, A., Cooper, T., and Kane, J. (1994) Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients, Am. J Psychiatry 151, 35-39.

    PubMed  CAS  Google Scholar 

  72. Zhang-Wong, J., Zipursky, R.B., Beiser, M., and Bean, G. (1999) Optimal haloperidol dosage in first-episode psychosis, Can. J. Psychiatry 44, 164-167.

    PubMed  CAS  Google Scholar 

  73. McCreadie, R.G., Mackie, M., Wiles, D.H., Jorgensen, A., Hansen, V., and Menzies, C. (1984) Within-individual variation in steady state plasma levels of different neuroleptics and prolactin, Br. J. Psychiatry 144, 625-629.

    Article  PubMed  CAS  Google Scholar 

  74. McIntyre, I.M., and Gershon, S. (1985) Interpatient variations in antipsychotic therapy, J Clin. Psychiatry 46, 3-5.

    PubMed  CAS  Google Scholar 

  75. Benes, F.M., Paskevich, P.A., and Domesick, V.B. (1983) Haloperidol-induced plasticity of axon terminals in rat substantia nigra, Science 221, 969-971.

    Article  PubMed  CAS  Google Scholar 

  76. Tarazi, F.I., Florijn, W.J., and Creese, I. (1997) Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment, Neuroscience 78, 985-996.

    Article  PubMed  CAS  Google Scholar 

  77. Schroder, J., Silvestri, S., Bubeck, B., Karr, M., Demisch, S., Scherrer, S., Gelder, F.J., and Sauer, H. (1998) D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 1231-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment, Biol. Psychiatry 43,660-665.

    Article  PubMed  CAS  Google Scholar 

  78. Silvestri, S., Seeman, M., Negrete, S., Houle, S., Shammi, C.M., Remington, G.J., Kapur, S., Zipursky, R.B., Wilson, A., Christensen B.K., and Seeman, P. (1999) Dopamine D2 upregulation and 5HT2 downregulation measured after neuroleptic withdrawal using PET, Schizophr. Res. 36, 247.

    Google Scholar 

  79. Bollini, P., Pampallona, S., Orza, M.J., Adams, M.E., and Chalmers, T.C. (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials, Psychol. Med. 24, 307-316.

    Article  PubMed  CAS  Google Scholar 

  80. McEvoy, J.P., Hogarty, G.E., and Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose, Arch. Gen. Psychiatry 48, 739-745.

    Article  PubMed  CAS  Google Scholar 

  81. Stone, C.K., Garver, D.L., Griffith, J., Hirschowitz, J., and Bennett, J. (1995) Further evidence of a dose-response threshold for haloperidol in psychosis, Am. J. Psychiatry 152, 1210-1212.

    PubMed  CAS  Google Scholar 

  82. American Psychiatric Association. (1997) Practice guideline for the treatment of patients with schizophrenia, Am. J Psychiatry 154 1-63.,

    Google Scholar 

  83. Seeman, P., and Tallerico, T. (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine, Am. J. Psychiatry 156 876-884.,

    PubMed  CAS  Google Scholar 

  84. Kapur, S. (1998) A new framework for investigating antipsychotic action in humans: lessons from PET imaging, Mol. Psychiatry 3 135-140.,

    Article  PubMed  CAS  Google Scholar 

  85. Jones, C., Kapur, S., Zipursky, R.B., Remington, G., and Houle, S. (1999) Antipsychotic action with low D2 occupancy - a study of quetiapine, International Congress on Schizophrenia Research, Santa Fe, New Mexico.

    Google Scholar 

  86. Kapur, S., Ziursky, R., Jones, C., Shammi, C.S., Remington, G., Seeman, P. (submitted) Antipsychotic effect with only transient D2 occupancy: a clinical PET study of quetiapine, Am. J Psychiatry

    Google Scholar 

  87. Kissling, W. (1991) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia, Springer-Verlag, Berlin.

    Book  Google Scholar 

  88. The Scottish Schizophrenia Research Group. (1992) The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings, Br. J Psychiatry 161 496-500.,

    Article  Google Scholar 

  89. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., and Lieberman, J.A. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch. Gen. Psychiatry 56 241-247.,

    Article  PubMed  CAS  Google Scholar 

  90. Bartko, G., Maylath, E., and Herczeg, I. (1987) Comparative study of schizophrenic patients relapsed on and off medication, Psychiatry Res. 22 221-227.,

    Article  PubMed  CAS  Google Scholar 

  91. Hogarty, G.E. (1993) Prevention of relapse in chronic schizophrenic patients, J Clin. Psychiatry 54 iSuppl.J, 18-23.

    Google Scholar 

  92. Davis, J.M., Kane, J.M., Marder, S.R., Brauzer, B., Gierl, B., Schooler, N., Casey, D.E., and Hassan, M. (1993) Dose response of prophylactic antipsychotics, J. Clin. Psychiatry 54 ISuppl.J, 24-30.

    PubMed  Google Scholar 

  93. Johnstone, E.C., and Geddes, J. (1994) How high is the relapse rate in schizophrenia?, Acta Psychiatr Scand89 ISuppl. 38216-10.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schizophrenia and Continuing Care Program Clarke Division Centre for Addiction & Mental Health, Department of Psychiatry University of Toronto, Toronto, Ontario, Canada

    Gary Remington MD, PhD, FRCPC, Shitij Kapur MD, PhD, FRCPC & Bob Zipursky MD, FRCPC

Authors
  1. Gary Remington MD, PhD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shitij Kapur MD, PhD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bob Zipursky MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Yale University, New Haven, CT, USA

    Tandy Miller  & Thomas H. McGlashan  & 

  2. Social Science Research Institute, University of California, Los Angeles, CA, USA

    Sarnoff A. Mednick

  3. Psychiatric Center Prague, Prague, Czech Republic

    Jan Libiger

  4. Rogaland Psychiatric Hospital, Stavanger, Norway

    Jan Olav Johannessen

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Remington, G., Kapur, S., Zipursky, B. (2001). Pharmacotherapy of First Episode Psychosis. In: Miller, T., Mednick, S.A., McGlashan, T.H., Libiger, J., Johannessen, J.O. (eds) Early Intervention in Psychotic Disorders. NATO Science Series, vol 91. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0892-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-0892-1_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-0-7923-6750-5

  • Online ISBN: 978-94-010-0892-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation